Edward Nash
Stock Analyst at Canaccord Genuity
(4.30)
# 459
Out of 4,761 analysts
76
Total ratings
48.48%
Success rate
19.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $67.96 | +5.94% | 9 | Feb 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $22 → $45 | $21.98 | +104.73% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $3.08 | +29.87% | 2 | Feb 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $78 → $130 | $63.54 | +104.60% | 6 | Jan 30, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $51.84 | +40.82% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $34.55 | +157.60% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $1.61 | +769.57% | 6 | Aug 12, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $1.20 | +566.67% | 3 | May 23, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $2.84 | +604.23% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $1.66 | +442.17% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $338 → $377 | $336.23 | +12.13% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $1.85 | +333.60% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $4.53 | +275.28% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.15 | -6.98% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $2.70 | +6,559.02% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $42.59 | +92.53% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $3.94 | +1,930.46% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $12.84 | +273.83% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.78 | +11,145.67% | 1 | Nov 8, 2017 |
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $67.96
Upside: +5.94%
Travere Therapeutics
Feb 12, 2025
Maintains: Buy
Price Target: $22 → $45
Current: $21.98
Upside: +104.73%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $3.08
Upside: +29.87%
Corcept Therapeutics
Jan 30, 2025
Maintains: Buy
Price Target: $78 → $130
Current: $63.54
Upside: +104.60%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $51.84
Upside: +40.82%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $34.55
Upside: +157.60%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $1.61
Upside: +769.57%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.20
Upside: +566.67%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $2.84
Upside: +604.23%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $1.66
Upside: +442.17%
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $336.23
Upside: +12.13%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.85
Upside: +333.60%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.53
Upside: +275.28%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.15
Upside: -6.98%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $2.70
Upside: +6,559.02%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $42.59
Upside: +92.53%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $3.94
Upside: +1,930.46%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $12.84
Upside: +273.83%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.78
Upside: +11,145.67%